A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

To join this study, your doctor will first check if you meet certain requirements. You need to have mantle cell lymphoma that has either come back or isn't responding to treatment, and you must have already tried at least one other treatment, including a type of drug called a BTK inhibitor.

You also need to be well enough to take part, meaning you can carry out most of your normal daily activities. Doctors will check this, along with some blood tests to make sure your body is working properly. They'll also need to see if your cancer can be measured on scans and confirm that you have a certain type of mantle cell lymphoma. You would need to be at least 18 years old.

There are also some reasons why you might not be able to join. For example, if you are pregnant or breastfeeding, or planning to become pregnant soon. If you've previously had similar medicines to glofitamab, or certain other types of cancer treatment like CAR-T cell therapy, you wouldn't be able to join. Also, if you have certain other serious health conditions, particularly affecting your brain or spine, or if you're allergic to specific medications, you might not be eligible. Your doctor will go through all of these points with you carefully.

If you decide to take part in this study, you would either receive the new drug, glofitamab, or one of the standard treatment options. You wouldn't be able to choose which treatment you receive; this would be decided randomly, like flipping a coin, but your doctors won't know which one you're getting either.

Taking part would involve regular visits to the hospital or clinic. During these visits, doctors would give you your medication, and you'd have various tests, including blood tests and scans, to see how the treatment is working and to check for any side effects. These assessments are crucial for monitoring your health and the progress of your lymphoma. The exact number and frequency of visits will depend on the specific treatment you receive, but you should expect to be seen regularly for treatment cycles and follow-up checks.

After your treatment period, there would also be a follow-up phase where doctors would continue to monitor your health over time to see the long-term effects of the treatment. The total duration of your participation, including treatment and follow-up, could vary, but the study team will explain the full timeline to you in detail.